DiaMedica completes cGMP manufacturing, GLP toxicology studies of DM-199 compound
The completion of cGMP manufacturing, which resulted in a high yield batch of DM-199, allows the company to use DM-199 compound in its upcoming clinical trials. The company
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.